Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: A new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II)

  • Authors:
    • Yasuhiro Ogawa
    • Kei Kubota
    • Hironobu Ue
    • Yuko Kataoka
    • Michiko Tadokoro
    • Kana Miyatake
    • Kazuhiro Tsuzuki
    • Tomoaki Yamanishi
    • Satoshi Itoh
    • Jiro Hitomi
    • Norihiko Hamada
    • Shinji Kariya
    • Mitsutaka Fukumoto
    • Akihito Nishioka
    • Taisuke Inomata
  • View Affiliations

  • Published online on: March 1, 2009     https://doi.org/10.3892/ijo_00000186
  • Pages: 609-618
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Using a currently employed linear accelerator, our intent was to inactivate peroxidase/catalase in tumor tissue by the application of hydrogen peroxide, which is degraded to produce oxygen, thus re-oxygenizing the tumor tissue. In this way, we can convert radioresistant tumors into radiosensitive ones. On the basis of this strategy, we previously developed a new enzyme-targeting radiosensitization treatment named KORTUC I, which remarkably enhances the radiotherapeutic effect on various types of superficially exposed and locally advanced malignant neoplasms. Based on our clinical experience using KORTUC I, we also developed a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for injection into various types of tumors that are not superficially exposed (KORTUC II; described herein). KORTUC II was approved by our local ethics committee for advanced skin cancer, including malignant melanoma, bone/soft tissue malignant neoplasms, breast cancer, and metastatic lymph nodes. A maximum of 6 ml of the agent was injected into tumor tissue one to two times per week under ultrasonographic guidance, just prior to each administration of radiation therapy. Eleven patients, including seven with breast cancer, were enrolled in the KORTUC II trial upon fully informed consent. KORTUC II was well tolerated, with a minimum of adverse effects. Nine of the 11 patients showed a complete response (CR), and no severe complications occurred in any of the 11 patients. This new enzyme-targeting radiosensitization treatment may be indicated for various types of locally advanced neoplasms, including soft tissue neoplasms and breast cancers.

Related Articles

Journal Cover

March 2009
Volume 34 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ogawa Y, Kubota K, Ue H, Kataoka Y, Tadokoro M, Miyatake K, Tsuzuki K, Yamanishi T, Itoh S, Hitomi J, Hitomi J, et al: Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: A new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Int J Oncol 34: 609-618, 2009
APA
Ogawa, Y., Kubota, K., Ue, H., Kataoka, Y., Tadokoro, M., Miyatake, K. ... Inomata, T. (2009). Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: A new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). International Journal of Oncology, 34, 609-618. https://doi.org/10.3892/ijo_00000186
MLA
Ogawa, Y., Kubota, K., Ue, H., Kataoka, Y., Tadokoro, M., Miyatake, K., Tsuzuki, K., Yamanishi, T., Itoh, S., Hitomi, J., Hamada, N., Kariya, S., Fukumoto, M., Nishioka, A., Inomata, T."Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: A new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II)". International Journal of Oncology 34.3 (2009): 609-618.
Chicago
Ogawa, Y., Kubota, K., Ue, H., Kataoka, Y., Tadokoro, M., Miyatake, K., Tsuzuki, K., Yamanishi, T., Itoh, S., Hitomi, J., Hamada, N., Kariya, S., Fukumoto, M., Nishioka, A., Inomata, T."Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: A new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II)". International Journal of Oncology 34, no. 3 (2009): 609-618. https://doi.org/10.3892/ijo_00000186